The advent of sentinel lymph node biopsy has revolutionised surgical management of axillary nodal disease in patients with breast cancer. Patients undergoing neo-adjuvant chemotherapy for large breast primary tumours may experience complete pathological response on a previously positive sentinel node whilst not eliminating the tumour from the other lymph nodes. Results from 2 large prospective cohort studies investigating sentinel lymph node biopsy after neo-adjuvant chemotherapy demonstrate a combined false negative rate of 12.6-14.2% and identification rate of 80-89% with the minimal acceptable false negative rate and identification rate being set at 10% and 90%, respectively. A false negative rate of 14% would have been classified as unacceptable when compared to the figures obtained by the pioneers of sentinel lymph node biopsy which was 5% or less.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.breast.2015.02.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sentinel lymph node biopsy in breast cancer: the role of ICG fluorescence after neoadjuvant chemotherapy.
Breast Cancer Res Treat
January 2025
Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080, Lublin, Poland.
Purpose: The purpose of this study was to evaluate the feasibility and safety of indocyanine green (ICG) fluorescence as an alternative to traditional sentinel lymph node biopsy (SLNB) techniques in breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NAC). Specifically, the study aimed to assess sentinel node identification rates and the effectiveness of ICG in axillary staging without the use of radioactive tracers.
Methods: This retrospective study included 71 BC patients treated with NAC, who underwent SLNB using ICG fluorescence between 2020 and 2024.
Rhabdomyosarcoma Surgical Update.
Pediatr Blood Cancer
January 2025
Division of Pediatric Surgery, Kentucky Children's Hospital, University of Kentucky, Lexington, Kentucky, USA.
Rhabdomyosarcoma (RMS) tumors arise from mesenchymal tissue and represent half of pediatric sarcomas, which in turn make up 7% of pediatric tumors. Advances in local control therapy of RMS have improved outcomes after surgical resection of the primary tumor, either before or after induction chemotherapy, even in the setting of metastatic disease. The utilization of diagnostic core needle and sentinel node biopsy techniques for lymph node staging are becoming more widely used.
View Article and Find Full Text PDFTiming of sentinel lymph node biopsy and lymphoscintigraphy before surgery for melanoma: A systematic review and meta-analysis.
J Plast Reconstr Aesthet Surg
November 2024
Department of Plastic Surgery, Nottingham City Hospital, Nottingham, England, United Kingdom. Electronic address:
Introduction: The management of malignant melanomas often involves performing a sentinel lymph node biopsy (SLNB) aided by imaging with lymphoscintigraphy. Whether lymphoscintigraphy should be performed on the same day as the SLNB operation (SD) or the day before (DB) surgery remains debated. This study aims to summarise existing evidence regarding the impact of the relative timings of lymphoscintigraphy and SLNB on clinical outcomes in melanoma.
View Article and Find Full Text PDFReply to "De-escalation of axillary surgery in patients with sentinel lymph node micrometastases after neoadjuvant systemic therapy".
Cancer
January 2025
Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, South Korea.
De-escalation of axillary surgery in patients with sentinel lymph node micrometastases after neoadjuvant systemic therapy.
Cancer
January 2025
The London Breast Institute, Princess Grace Hospital, London, UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!